Protein Therapeutics Market By Type (Monoclonal Antibodies, Recombinant Proteins, Vaccines, Enzyme Replacement Therapy, Blood Factors), By Application (Oncology, Neurology, Hematology, Infectious Diseases, Cardiovascular), By End-User (Pharmaceutical Companies, Biotech Companies, Contract Research Organizations (CROs), Hospitals and Clinics, Research Institutes), By Component (Proteins, Antibodies, Enzymes, Hormones); Global Insights & Forecast (2024 - 2030)

As per Intent Market Research, the Protein Therapeutics Market was valued at USD 314.7 Billion in 2024-e and will surpass USD 471.8 Billion by 2030; growing at a CAGR of 7.0% during 2025 - 2030.

The protein therapeutics market has emerged as a critical segment within the global pharmaceutical and biotechnology industries. Protein therapeutics, which include a wide range of biologic products such as monoclonal antibodies, recombinant proteins, and vaccines, are increasingly used to treat various complex diseases. These treatments have revolutionized modern medicine, especially in oncology, neurology, and hematology, where traditional small-molecule drugs may not be as effective. The growing prevalence of chronic diseases and advancements in biotechnological research are driving the demand for protein-based therapies. With increasing investments in biologic research and the ongoing development of novel therapies, the protein therapeutics market is expected to witness significant growth in the coming years.

The global protein therapeutics market is characterized by high levels of innovation, with major players investing in the development of next-generation biologics. As the demand for personalized medicine grows, there is a notable shift toward precision therapies that target specific molecular pathways, improving treatment efficacy and minimizing side effects. The expansion of biologic manufacturing capabilities and the growing acceptance of protein therapeutics are expected to create new opportunities across a wide range of applications and therapeutic areas.

Monoclonal Antibodies Are the Largest Type Due to Their Versatility and Efficacy

Monoclonal antibodies (mAbs) are the largest type within the protein therapeutics market, primarily due to their broad applicability in treating a wide array of diseases, particularly cancer, autoimmune disorders, and infectious diseases. These highly specific antibodies are designed to target particular antigens found on the surface of cells, enabling highly targeted therapies with minimal off-target effects. Monoclonal antibodies are widely used in oncology, where they are employed in targeted cancer therapies, offering better outcomes and fewer side effects compared to traditional chemotherapy.

The versatility of mAbs in targeting specific immune pathways and their ability to be engineered for enhanced functionality have solidified their position as a dominant therapeutic modality. Recent advancements, such as bispecific antibodies and antibody-drug conjugates, further expand the scope of mAbs, enabling more effective and tailored treatments. Given the rising prevalence of cancer and autoimmune diseases, monoclonal antibodies are expected to remain a central component of the protein therapeutics market, with new innovations continuing to fuel market expansion.

Oncology Is the Leading Application Segment Due to the High Prevalence of Cancer

Oncology is the leading application segment in the protein therapeutics market, driven by the increasing incidence of cancer and the growing demand for effective and targeted therapies. Cancer is one of the most prevalent diseases globally, and protein-based therapeutics, particularly monoclonal antibodies and recombinant proteins, have shown significant promise in treating various types of cancer. These therapies offer several advantages, including the ability to target cancer cells more specifically, thereby reducing damage to surrounding healthy tissue and minimizing side effects.

The development of immunotherapies, including checkpoint inhibitors and CAR-T cell therapies, has revolutionized the treatment of cancers such as melanoma, non-small cell lung cancer, and leukemia. These advancements in cancer treatment have contributed to the substantial growth of the oncology application segment in the protein therapeutics market. As the demand for more effective and personalized cancer treatments rises, the oncology segment is expected to continue to lead market growth.

Pharmaceutical Companies Are the Dominant End-User Segment Due to Their Research and Development Capabilities

Pharmaceutical companies are the dominant end-user segment in the protein therapeutics market, primarily due to their extensive research and development (R&D) capabilities and their role in the commercialization of protein-based therapies. These companies invest heavily in the development of novel biologic therapies and have the infrastructure required to scale production and bring these therapeutics to market. The ongoing research in areas such as oncology, neurology, and immunology has further accelerated the demand for protein therapeutics, as pharmaceutical companies strive to develop new treatments for complex and unmet medical needs.

The increasing focus on biologics, as opposed to traditional small-molecule drugs, has driven pharmaceutical companies to expand their R&D pipelines to include more protein-based therapies. Additionally, collaborations between pharmaceutical companies and biotechnology firms have enabled the development of cutting-edge biologics. As pharmaceutical companies continue to lead in the commercialization of protein therapeutics, they will play a pivotal role in the market's future growth.

Proteins Are the Largest Component Segment Due to Their Fundamental Role in Protein Therapeutics

Proteins represent the largest component segment in the protein therapeutics market, as they form the backbone of biologic therapies such as monoclonal antibodies, recombinant proteins, and vaccines. Proteins are critical for the biological activity of these therapeutics, which are designed to interact with specific targets in the body to elicit therapeutic effects. The production and purification of proteins are complex processes that require advanced biotechnology techniques, such as recombinant DNA technology and cell culture systems.

As protein-based therapies become more advanced and specialized, the demand for high-quality, scalable protein production methods continues to rise. The ongoing development of novel protein therapeutics, including bispecific antibodies and protein-based vaccines, will drive further growth in the protein component segment. With the increasing focus on personalized and precision medicine, proteins will remain a cornerstone of the protein therapeutics market.

North America Leads the Market Due to Robust Healthcare Infrastructure and Biotech Advancements

North America is the largest region in the protein therapeutics market, driven by the region's strong healthcare infrastructure, advanced biotechnology industry, and high investment in medical research. The United States, in particular, is home to numerous leading pharmaceutical companies, biotech firms, and research institutions that are at the forefront of developing and commercializing protein-based therapies. North America's well-established regulatory framework and significant healthcare spending further contribute to the region's dominance in the protein therapeutics market.

In addition, the growing focus on personalized medicine and the increasing prevalence of chronic diseases such as cancer and autoimmune disorders have further accelerated the demand for protein therapeutics in North America. The region's leading position in biologics manufacturing and research will ensure that it remains a key market for protein therapeutics in the coming years.

Competitive Landscape: Key Players and Market Dynamics

The protein therapeutics market is highly competitive, with several major players leading the development and commercialization of biologic therapies. Key companies in the market include Amgen Inc., Genentech Inc. (Roche), AbbVie Inc., Merck & Co., and Eli Lilly and Company. These companies have a strong presence in various therapeutic areas such as oncology, neurology, and immunology, and they continue to invest in R&D to bring innovative protein-based therapies to market.

In addition to established players, there are several biotechnology companies that are developing novel protein therapeutics and forming strategic partnerships with pharmaceutical companies to advance their product pipelines. As the market grows, competition is expected to intensify, with companies increasingly focusing on developing next-generation biologics that offer improved efficacy, safety, and specificity. Moreover, collaborations, mergers, and acquisitions will continue to shape the competitive dynamics of the protein therapeutics market, enabling companies to expand their portfolios and address the growing demand for protein-based therapies.

List of Leading Companies:

• Amgen Inc.
• Roche Holding AG
• AbbVie Inc.
• Johnson & Johnson
• Pfizer Inc.
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Sanofi S.A.
• Eli Lilly and Co.
• Novartis International AG
• GSK plc
• Regeneron Pharmaceuticals
• Mylan N.V. (now part of Viatris)
• Celltrion Inc.
• Samsung Biologics

Recent Developments:

• Amgen Inc. received FDA approval for a new monoclonal antibody treatment for cancer in January 2025.
• Roche Holding AG launched a new biosimilar protein therapeutic for rheumatoid arthritis in December 2024.
• Pfizer Inc. entered into a partnership with a biotech firm to co-develop a new enzyme replacement therapy in November 2024.
• Eli Lilly and Co. acquired a small biotech company focused on protein-based immunotherapy for neurological diseases in October 2024.
• Merck & Co., Inc. announced the approval of its new protein therapeutic for cardiovascular disease treatment in September 2024.

Report Scope: